Mainboard
IPO ·
BSE, NSE
Symbiotec Pharmalab Ltd
Listed
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products
Issue details
Price band
₹938 – ₹988
Face value
₹2
Lot size
15 shares
Minimum investment
₹14,820
Issue size
₹1757.00 Cr
Fresh issue
₹150.27 Cr
Offer for sale
₹1606.72 Cr
Issue type
Book Built
Exchange
BSE, NSE
Key dates
Opens
24 Aug 2026
Closes
27 Aug 2026
UPI mandate cut-off
5:00 PM on 27 Aug 2026
Allotment
28 Aug 2026
Refunds
31 Aug 2026
Shares in demat
31 Aug 2026
Listing
1 Sep 2026
Subscription and listing
Subscription
52.66x
Listing price
₹988
Registrar
MUFG Intime India Pvt Ltd
Lead manager
JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, Nomura Financial Advisory & Securities (India)
Subscription by category
Total
52.66x
Total applications
51,73,227
Anchor investors
Amount raised
₹526.20 Cr
Bid date
21 Aug 2026
50% lock-in ends
26 Sep 2026
Rest lock-in ends
25 Nov 2026
Listing day
Issue price
₹988
Open
₹988.00
High
₹1,180.00
Low
₹934.20
Day close
₹1,097.70
Listing gain at open
0.00%
Issue structure
Shares reserved per category and share of the total issue
QIB
88,76,516
49.91%
Anchor Investor
53,25,909
29.94%
QIB (Ex. Anchor)
35,50,607
19.96%
NII
26,62,956
14.97%
bNII > ₹10L
17,75,304
9.98%
sNII < ₹10L
8,87,652
4.99%
Retail
62,13,563
34.93%
Employee
33,407
0.19%
Total
1,77,86,442
100.00%
Finaccle’s quick read
Avoid
FY26 income up 15%, PAT up 14%, ROE 11.19%, post-issue P/E 57.78x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
11.19%
ROCE
11.56%
Debt / equity
—
PAT margin
12.60%
P/E post issue
57.78
Market cap
₹6,348.50 Cr
Use of IPO money
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
₹112.50 Cr
General Corporate Purposes
₹29.53 Cr
Issue Expenses
₹105.02 Cr
Strengths
✓
: Global leadership in corticosteroid and steroidal hormone APIs
✓
Long-standing relationships with domestic and international customers
✓
Revenue up 15% in FY26 to ₹872.26 Cr
✓
PAT margin of 12.60%
Risks to watch
!
Rich valuation: post-issue P/E of 57.78x
!
91% of issue is an offer for sale; company gets less fresh money
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.